Archive for September, 2009

Comparison of various antiandrogens

Friday, September 25th, 2009

The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 89-94
Copyright © 2000 by The Endocrine Society

Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial1

Paolo Moghetti, Flavia Tosi, Antonella Tosti, Carlo Negri, Cosimo Misciali, Fabrizia Perrone, Marco Caputo, Michele Muggeo and Roberto Castello

To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months. Before and at the end of treatment, hirsutism was quantitatively measured in each subject by determination, by computer-assisted light microscopy, of the largest diameter of 5 hairs plucked from the linea alba. These measurements were averaged to produce a mean hair shaft diameter. For each subject, baseline and posttreatment assessments were carried out at the same time by an investigator blinded to both time and type of therapy. In addition, a semiquantitative clinical evaluation was carried out by a modification of the Ferriman-Gallwey (F-G) scoring method, performed by a single investigator. At baseline the 4 groups of women had similar hair diameters and F-G scores. After 6 months of therapy all groups of subjects given active drugs showed reductions of their hair diameters, without statistically significant differences among groups (mean change ± SEM, -11.7 ± 5.6%, -18.0 ± 6.1%, and -12.6 ± 6.7%, respectively, in the spironolactone, flutamide, and finasteride groups). F-G scores were also significantly reduced in women receiving antiandrogen drugs, again without differences among groups (mean change, -41.0 ± 5.5%, -38.9 ± 7.2%, and -31.6 ± 3.7%, respectively). No significant changes from baseline values were recorded by either hair diameter (-1.4 ± 5.2%) or F-G score (+5.4 ± 3.7%) assessment in the placebo group. In conclusion, spironolactone, flutamide, and finasteride are all effective in the treatment of hirsutism. After a 6-month course of therapy, the clinical efficacies of these drugs, at least at the doses used, are similar.

Hair Loss treatment

Finasteride for pattern hair loss treatment

Friday, September 25th, 2009

Biomed Pharmacother. 1995;49(7-8):319-24

Finasteride: a clinical review.
Gormley GJ.
Merck Research Laboratories, Rahway, NJ 07065-0914, USA.

Hair Loss Blog

Finasteride is the first of a new class of 5 alpha-reductase inhibitors which allows selective androgen deprivation affecting dihydrotestosterone (DHT) levels in target organs such as the prostate and scalp hair without effecting circulating levels of testosterone thus preserving the desired androgen mediated effects on muscle strength, bone density and sexual function. Finasteride has been demonstrated to produce significant effects in men with an enlarged prostate gland. The long-term data now emerging suggests that progression of benign prostatic hyperplasia (BPH) may be arrested providing additional long term benefits. Experimental uses in prostate cancer prevention and male pattern baldness offer new and exciting possibilities for this class of compounds.

Hair Loss Treatment Blog

Monday, September 7th, 2009

Hair Loss Treatment blog

Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil

Monday, September 7th, 2009

J Invest Dermatol. 1990 Dec;95(6):683-7.  Links

Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil.

Price VH, Menefee E.

Department of Dermatology, Kaiser Permanente Medical Center, San Francisco, California.

Quantitative growth of hair over a 40-week period is reported for eight women with androgenetic alopecia. Using a random, double-blind protocol, the women were given either a 2% minoxidil solution or a placebo of vehicle only. Hair in a permanently marked site on the fronto-parietal scalp was pulled through a 1-cm-square clear plastic template, and the outline of the template was drawn on the scalp. The hair was carefully hand clipped and collected at five eight-week intervals (one untreated and four treated), using great care to collect only hairs within the marked area. Subsequent measurements included the total weight of hair grown in the marked area, the total number of hairs, and, on a randomized 50-hair subsample, the weight, lengths, and optical diameters. Calculated quantities included average weight per hair, average length, and average optical width. The average total hair weight of minoxidil-treated subjects increased over the 32-week test period by 42.5%, compared to 1.9% for the placebo-treated subjects (average p = 0.018). Changes for the average number count were 29.9% and -2.6%, respectively (average p = 0.022). These increases, observed using an unusually small number of subjects, clearly distinguished the treated subjects from the untreated. During the same test period, the averaged quantities of weight, diameter, and length from the 50-hair subsample showed insignificant change (p usually greater than 0.5). In addition to showing a larger percentage increase than did the total number, the total weight is not only easier to obtain, but less prone to error during sampling and measurement. Therefore, we recommend that total weight from a defined area be considered as the primary quantitative estimator for  hair regrowth.

Hello world!

Monday, September 7th, 2009

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!